Loss of periplakin expression is associated with pathological stage and cancer-specific survival in patients with urothelial carcinoma of the urinary bladder
The objective of this study was to determine periplakin expression in normal urothelium and bladder cancer tissues and the relationship to clinicopathological findings. Immunohistochemical staining for periplakin was carried out in 92 archival radical cystectomy specimens, with immunoreactivity bein...
Gespeichert in:
| Veröffentlicht in: | Biomedical research (Tokyo) 2014-06, Vol.35 (3), p.201-206 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 206 |
|---|---|
| container_issue | 3 |
| container_start_page | 201 |
| container_title | Biomedical research (Tokyo) |
| container_volume | 35 |
| creator | Matsumoto, Kazumasa Ikeda, Masaomi Sato, Yuichi Kuruma, Hidetoshi Kamata, Yuko Nishimori, Takanori Tomonaga, Tsuyoshi Nomura, Fumio Egawa, Shin Iwamura, Masatsugu |
| description | The objective of this study was to determine periplakin expression in normal urothelium and bladder cancer tissues and the relationship to clinicopathological findings. Immunohistochemical staining for periplakin was carried out in 92 archival radical cystectomy specimens, with immunoreactivity being stratified on a 0-6 scale. Immunohistochemical staining for periplakin was shown to be significantly lower in bladder cancer tissues compared to non-cancerous tissues including inflammation,hyperplasia and normal urothelium. Loss of periplakin expression was associated with pathological stage (P=0.04). In multivariate Cox regression analysis, loss of periplakin expression and positive lymph node status were independent prognostic factors for cancer-specific survival (P=0.03 and 0.015; odds ratio=2.29 and 2.66; 95% confidence interval=1.085-4.814 and 1.214-5.845, respectively). This new molecular marker may aid in identifying and selecting bladder cancer patients undergoing radical cystectomy who may potentially benefit from neoadjuvant or adjuvant therapy. |
| doi_str_mv | 10.2220/biomedres.35.201 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1539468676</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1539468676</sourcerecordid><originalsourceid>FETCH-LOGICAL-j235t-4c072070f879b7f740b616eb12a9781d8d6af96d55beec70d17530bec5bd5aaa3</originalsourceid><addsrcrecordid>eNo1kE9P3TAQxK1KFVDKnVPlYy95-E8cO8cKtRTpSVxA6u1pbW94pnlx6k0ofBi-a42gp5V2Zn4aDWPnUmyUUuLCp3zAWJA22myUkB_YiXRONFrqX8fsE9GDENpJp4_YsWr7VjnTn7CXbSbieeAzljSP8DtNHJ_miqGUJ56IA1EOCRaM_G9a9nyGZZ_HfJ8CjJwWuEcOU-QBpoCloRlDGlLgtJbH9FgtFVgjCaeF3gBrycsex1S1ACWkKR_gtUF9Vi1NUJ65HyFGLJ_ZxwFGwrP3e8rufny_vfzZbG-uri-_bZsHpc3StEFYJawYnO29HWwrfCc79FJBb52MLnYw9F00xiMGK6K0RguPwfhoAECfsq9v3LnkPyvSsjskCjiOMGFeaSeN7tvOdbar1i_v1tXXvXdzSYfaePd_Uv0P1DN9HQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1539468676</pqid></control><display><type>article</type><title>Loss of periplakin expression is associated with pathological stage and cancer-specific survival in patients with urothelial carcinoma of the urinary bladder</title><source>J-STAGE Free</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Matsumoto, Kazumasa ; Ikeda, Masaomi ; Sato, Yuichi ; Kuruma, Hidetoshi ; Kamata, Yuko ; Nishimori, Takanori ; Tomonaga, Tsuyoshi ; Nomura, Fumio ; Egawa, Shin ; Iwamura, Masatsugu</creator><creatorcontrib>Matsumoto, Kazumasa ; Ikeda, Masaomi ; Sato, Yuichi ; Kuruma, Hidetoshi ; Kamata, Yuko ; Nishimori, Takanori ; Tomonaga, Tsuyoshi ; Nomura, Fumio ; Egawa, Shin ; Iwamura, Masatsugu</creatorcontrib><description>The objective of this study was to determine periplakin expression in normal urothelium and bladder cancer tissues and the relationship to clinicopathological findings. Immunohistochemical staining for periplakin was carried out in 92 archival radical cystectomy specimens, with immunoreactivity being stratified on a 0-6 scale. Immunohistochemical staining for periplakin was shown to be significantly lower in bladder cancer tissues compared to non-cancerous tissues including inflammation,hyperplasia and normal urothelium. Loss of periplakin expression was associated with pathological stage (P=0.04). In multivariate Cox regression analysis, loss of periplakin expression and positive lymph node status were independent prognostic factors for cancer-specific survival (P=0.03 and 0.015; odds ratio=2.29 and 2.66; 95% confidence interval=1.085-4.814 and 1.214-5.845, respectively). This new molecular marker may aid in identifying and selecting bladder cancer patients undergoing radical cystectomy who may potentially benefit from neoadjuvant or adjuvant therapy.</description><identifier>EISSN: 1880-313X</identifier><identifier>DOI: 10.2220/biomedres.35.201</identifier><identifier>PMID: 24942859</identifier><language>eng</language><publisher>Japan</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Carcinoma, Transitional Cell - metabolism ; Carcinoma, Transitional Cell - mortality ; Carcinoma, Transitional Cell - pathology ; Carcinoma, Transitional Cell - therapy ; Female ; Follow-Up Studies ; Gene Expression ; Humans ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging ; Odds Ratio ; Plakins - genetics ; Plakins - metabolism ; Prognosis ; Urinary Bladder Neoplasms - metabolism ; Urinary Bladder Neoplasms - mortality ; Urinary Bladder Neoplasms - pathology ; Urinary Bladder Neoplasms - therapy</subject><ispartof>Biomedical research (Tokyo), 2014-06, Vol.35 (3), p.201-206</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24942859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsumoto, Kazumasa</creatorcontrib><creatorcontrib>Ikeda, Masaomi</creatorcontrib><creatorcontrib>Sato, Yuichi</creatorcontrib><creatorcontrib>Kuruma, Hidetoshi</creatorcontrib><creatorcontrib>Kamata, Yuko</creatorcontrib><creatorcontrib>Nishimori, Takanori</creatorcontrib><creatorcontrib>Tomonaga, Tsuyoshi</creatorcontrib><creatorcontrib>Nomura, Fumio</creatorcontrib><creatorcontrib>Egawa, Shin</creatorcontrib><creatorcontrib>Iwamura, Masatsugu</creatorcontrib><title>Loss of periplakin expression is associated with pathological stage and cancer-specific survival in patients with urothelial carcinoma of the urinary bladder</title><title>Biomedical research (Tokyo)</title><addtitle>Biomed Res</addtitle><description>The objective of this study was to determine periplakin expression in normal urothelium and bladder cancer tissues and the relationship to clinicopathological findings. Immunohistochemical staining for periplakin was carried out in 92 archival radical cystectomy specimens, with immunoreactivity being stratified on a 0-6 scale. Immunohistochemical staining for periplakin was shown to be significantly lower in bladder cancer tissues compared to non-cancerous tissues including inflammation,hyperplasia and normal urothelium. Loss of periplakin expression was associated with pathological stage (P=0.04). In multivariate Cox regression analysis, loss of periplakin expression and positive lymph node status were independent prognostic factors for cancer-specific survival (P=0.03 and 0.015; odds ratio=2.29 and 2.66; 95% confidence interval=1.085-4.814 and 1.214-5.845, respectively). This new molecular marker may aid in identifying and selecting bladder cancer patients undergoing radical cystectomy who may potentially benefit from neoadjuvant or adjuvant therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Transitional Cell - metabolism</subject><subject>Carcinoma, Transitional Cell - mortality</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Carcinoma, Transitional Cell - therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene Expression</subject><subject>Humans</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Odds Ratio</subject><subject>Plakins - genetics</subject><subject>Plakins - metabolism</subject><subject>Prognosis</subject><subject>Urinary Bladder Neoplasms - metabolism</subject><subject>Urinary Bladder Neoplasms - mortality</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - therapy</subject><issn>1880-313X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE9P3TAQxK1KFVDKnVPlYy95-E8cO8cKtRTpSVxA6u1pbW94pnlx6k0ofBi-a42gp5V2Zn4aDWPnUmyUUuLCp3zAWJA22myUkB_YiXRONFrqX8fsE9GDENpJp4_YsWr7VjnTn7CXbSbieeAzljSP8DtNHJ_miqGUJ56IA1EOCRaM_G9a9nyGZZ_HfJ8CjJwWuEcOU-QBpoCloRlDGlLgtJbH9FgtFVgjCaeF3gBrycsex1S1ACWkKR_gtUF9Vi1NUJ65HyFGLJ_ZxwFGwrP3e8rufny_vfzZbG-uri-_bZsHpc3StEFYJawYnO29HWwrfCc79FJBb52MLnYw9F00xiMGK6K0RguPwfhoAECfsq9v3LnkPyvSsjskCjiOMGFeaSeN7tvOdbar1i_v1tXXvXdzSYfaePd_Uv0P1DN9HQ</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Matsumoto, Kazumasa</creator><creator>Ikeda, Masaomi</creator><creator>Sato, Yuichi</creator><creator>Kuruma, Hidetoshi</creator><creator>Kamata, Yuko</creator><creator>Nishimori, Takanori</creator><creator>Tomonaga, Tsuyoshi</creator><creator>Nomura, Fumio</creator><creator>Egawa, Shin</creator><creator>Iwamura, Masatsugu</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20140601</creationdate><title>Loss of periplakin expression is associated with pathological stage and cancer-specific survival in patients with urothelial carcinoma of the urinary bladder</title><author>Matsumoto, Kazumasa ; Ikeda, Masaomi ; Sato, Yuichi ; Kuruma, Hidetoshi ; Kamata, Yuko ; Nishimori, Takanori ; Tomonaga, Tsuyoshi ; Nomura, Fumio ; Egawa, Shin ; Iwamura, Masatsugu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j235t-4c072070f879b7f740b616eb12a9781d8d6af96d55beec70d17530bec5bd5aaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Transitional Cell - metabolism</topic><topic>Carcinoma, Transitional Cell - mortality</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Carcinoma, Transitional Cell - therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene Expression</topic><topic>Humans</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Odds Ratio</topic><topic>Plakins - genetics</topic><topic>Plakins - metabolism</topic><topic>Prognosis</topic><topic>Urinary Bladder Neoplasms - metabolism</topic><topic>Urinary Bladder Neoplasms - mortality</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsumoto, Kazumasa</creatorcontrib><creatorcontrib>Ikeda, Masaomi</creatorcontrib><creatorcontrib>Sato, Yuichi</creatorcontrib><creatorcontrib>Kuruma, Hidetoshi</creatorcontrib><creatorcontrib>Kamata, Yuko</creatorcontrib><creatorcontrib>Nishimori, Takanori</creatorcontrib><creatorcontrib>Tomonaga, Tsuyoshi</creatorcontrib><creatorcontrib>Nomura, Fumio</creatorcontrib><creatorcontrib>Egawa, Shin</creatorcontrib><creatorcontrib>Iwamura, Masatsugu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedical research (Tokyo)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsumoto, Kazumasa</au><au>Ikeda, Masaomi</au><au>Sato, Yuichi</au><au>Kuruma, Hidetoshi</au><au>Kamata, Yuko</au><au>Nishimori, Takanori</au><au>Tomonaga, Tsuyoshi</au><au>Nomura, Fumio</au><au>Egawa, Shin</au><au>Iwamura, Masatsugu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Loss of periplakin expression is associated with pathological stage and cancer-specific survival in patients with urothelial carcinoma of the urinary bladder</atitle><jtitle>Biomedical research (Tokyo)</jtitle><addtitle>Biomed Res</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>35</volume><issue>3</issue><spage>201</spage><epage>206</epage><pages>201-206</pages><eissn>1880-313X</eissn><abstract>The objective of this study was to determine periplakin expression in normal urothelium and bladder cancer tissues and the relationship to clinicopathological findings. Immunohistochemical staining for periplakin was carried out in 92 archival radical cystectomy specimens, with immunoreactivity being stratified on a 0-6 scale. Immunohistochemical staining for periplakin was shown to be significantly lower in bladder cancer tissues compared to non-cancerous tissues including inflammation,hyperplasia and normal urothelium. Loss of periplakin expression was associated with pathological stage (P=0.04). In multivariate Cox regression analysis, loss of periplakin expression and positive lymph node status were independent prognostic factors for cancer-specific survival (P=0.03 and 0.015; odds ratio=2.29 and 2.66; 95% confidence interval=1.085-4.814 and 1.214-5.845, respectively). This new molecular marker may aid in identifying and selecting bladder cancer patients undergoing radical cystectomy who may potentially benefit from neoadjuvant or adjuvant therapy.</abstract><cop>Japan</cop><pmid>24942859</pmid><doi>10.2220/biomedres.35.201</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1880-313X |
| ispartof | Biomedical research (Tokyo), 2014-06, Vol.35 (3), p.201-206 |
| issn | 1880-313X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1539468676 |
| source | J-STAGE Free; MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Aged, 80 and over Carcinoma, Transitional Cell - metabolism Carcinoma, Transitional Cell - mortality Carcinoma, Transitional Cell - pathology Carcinoma, Transitional Cell - therapy Female Follow-Up Studies Gene Expression Humans Lymphatic Metastasis Male Middle Aged Neoplasm Staging Odds Ratio Plakins - genetics Plakins - metabolism Prognosis Urinary Bladder Neoplasms - metabolism Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - therapy |
| title | Loss of periplakin expression is associated with pathological stage and cancer-specific survival in patients with urothelial carcinoma of the urinary bladder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T10%3A42%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Loss%20of%20periplakin%20expression%20is%20associated%20with%20pathological%20stage%20and%20cancer-specific%20survival%20in%20patients%20with%20urothelial%20carcinoma%20of%20the%20urinary%20bladder&rft.jtitle=Biomedical%20research%20(Tokyo)&rft.au=Matsumoto,%20Kazumasa&rft.date=2014-06-01&rft.volume=35&rft.issue=3&rft.spage=201&rft.epage=206&rft.pages=201-206&rft.eissn=1880-313X&rft_id=info:doi/10.2220/biomedres.35.201&rft_dat=%3Cproquest_pubme%3E1539468676%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1539468676&rft_id=info:pmid/24942859&rfr_iscdi=true |